+44 (0) 1223 755950
+1 832 327 7413
Tibulizumab
REQUEST MORE INFO
Catalogue No: abx831453
Price:
US$435.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Tibulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17A/TNFSF13B/CD257, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tibulizumab is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
Research Articles on IL17A/TNFSF13B/CD257
| Target | IL17A/TNFSF13B/CD257 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG4 Kappa-[scFv]2 |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 1849636-24-3 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
